About the company
Management team
Board of directors
Team expertise
Key advisers
Dementia & Alzheimer's disease
Dementia in Down syndrome
The dementia market
Diabetes
The Science behind Pharmasum
Protein kinase DYRK1A
DYRK1A - Role in different diseases
Proprietary inhibitors of DYRK1A
SBDD – Structure-Based Drug Design
Pipeline
News Releases
For Investor Relations, please contact:
Anders Fugelli
CEO Pharmasum Therapeutics
Phone: +47 924 81 432
Email: afugelli@pharmasum.com
